FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.
- DOI
- 10.1186/s12885-021-08312-7
- Published
- 2021 May 17
- Container
- BMC cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12885-021-08312-7,
title = {FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.},
author = {Adenis A and Mazard T and Fraisse J and Chalbos P and Pastor B and Evesque L and Ghiringhelli F and Mollevi C and Delaine S and Ychou M},
year = {2021},
journal = {BMC cancer},
doi = {10.1186/s12885-021-08312-7},
url = {https://doi.org/10.1186/s12885-021-08312-7}
}RIS
TY - JOUR TI - FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer. AU - Adenis A AU - Mazard T AU - Fraisse J AU - Chalbos P AU - Pastor B AU - Evesque L AU - Ghiringhelli F AU - Mollevi C AU - Delaine S AU - Ychou M PY - 2021 JO - BMC cancer DO - 10.1186/s12885-021-08312-7 UR - https://doi.org/10.1186/s12885-021-08312-7 ER -
APA
A, A., T, M., J, F., P, C., B, P., L, E., F, G., C, M., S, D., & M, Y. (2021). FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.. BMC cancer. https://doi.org/10.1186/s12885-021-08312-7
Source records
- pubmed · retrieved 2026-09-26T14:31:09.991Z